Aion Therapeutic Inc represents values of innovation, excellence, and patient-centric care in the field of medical therapeutics. The company is committed to developing and providing novel and effective treatments for various medical conditions. Aion Therapeutic Inc embraces a corporate philosophy focused on advancing medical research, ensuring high-quality standards in product development, and delivering the best possible outcomes for patients. By leveraging cutting-edge technology and scientific expertise, the company aims to bring transformative solutions to the healthcare industry. Aion Therapeutic Inc prioritizes a holistic approach, working towards improving the well-being and quality of life for individuals in need of medical interventions.

Aion Therapeutic Inc is primarily present in the United States and Canada.

Aion Therapeutic Inc, a renowned biotech company, has achieved several significant milestones throughout its history. These milestones highlight the company's commitment to innovation and advancement in the field of therapeutics. Some of their notable accomplishments include successful clinical trials for their groundbreaking drug candidates, strategic partnerships with leading research institutions, and obtaining crucial regulatory approvals. The company's dedication to research and development has allowed them to make remarkable progress in improving patient care and finding effective treatment solutions. Aion Therapeutic Inc's relentless pursuit of scientific excellence demonstrates their commitment to shaping the future of the pharmaceutical industry.

Aion Therapeutic Inc is a company specializing in the development and commercialization of innovative therapies and technologies for the medical cannabis industry. Founded in [year], Aion Therapeutic Inc has established itself as a leading player in the global market. The company is dedicated to discovering and advancing unique cannabis-based treatments for various medical conditions. With an experienced team of professionals and strategic partnerships, Aion Therapeutic Inc is committed to revolutionizing the healthcare industry with its cutting-edge solutions. By combining scientific expertise with a patient-centric approach, the company aims to improve the quality of life for individuals worldwide.

Some of the main competitors of Aion Therapeutic Inc in the market include companies like GW Pharmaceuticals, Tilray Inc, and Canopy Growth Corporation.

Aion Therapeutic Inc is primarily active in the pharmaceutical and biotechnology industries.

The business model of Aion Therapeutic Inc. focuses on researching and developing treatments for various mental health conditions. As a pharmaceutical company, Aion Therapeutic Inc. aims to create innovative and effective therapies using psychedelic compounds. By leveraging its expertise in drug development, the company explores the potential of compounds such as psilocybin in treating conditions like PTSD, depression, and anxiety disorders. Through strategic partnerships and collaborations, Aion Therapeutic Inc. seeks to advance psychedelic-assisted therapy, bringing relief and improved mental well-being to individuals worldwide.

Pašreizējais KGV Aion Therapeutic nevar tikt aprēķināts.

KUV šobrīd Aion Therapeutic nevar aprēķināt.

AlleAktien kvalitātes vērtējums Aion Therapeutic ir 3/10.

Pašreiz nevar aprēķināt apgrozījumu Aion Therapeutic.

Pašlaik peļņa Aion Therapeutic nevar tikt aprēķināta.

Aion Therapeutic Inc is a rising Canadian biotechnology company focused on researching and developing innovative, evidence-based medical cannabis products. The company is headquartered in Ontario, Canada, and is listed on the Canadian stock exchange under the symbol "AION." The business model of Aion Therapeutic Inc is centered around creating medical cannabis products that target specific medical conditions. The company focuses on three main areas: research and development, production, and distribution. Research and Development Aion Therapeutic Inc maintains a dedicated research team focused on developing cannabinoid-based therapy options. The company has developed a wide range of technologies and processes to produce cannabis extracts tailored to specific medical conditions. The company has made history in the past by being the first to produce a synthetic form of psilocybin, the active ingredient in magic mushrooms, which is also commonly used as a hallucinogen in scientific research. Production The company operates multiple production facilities in Canada to ensure the highest quality raw materials. It also utilizes the latest technologies to enhance the effectiveness of its products. Aion Therapeutic Inc offers a wide range of products, including various cannabinoid oils, capsules, sprays, and topical products. The company also has a pipeline of products in development targeting specific conditions such as anxiety and sleep disorders. Distribution The company employs a multi-channel distribution strategy to sell its products worldwide. Aion Therapeutic Inc has distribution agreements with various partners and focuses on direct sales through online shops, as well as retail stores and pharmacies. In addition to its core activities, the company also engages in acquiring and investing in innovative technologies and companies. It has already made an acquisition in the water treatment sector. SEO Optimization To adhere to SEO guidelines, strategic keywords such as cannabis products, medical cannabinoids, research and development, technologies, Canada, and Aion Therapeutic Inc have been used as examples in the text. Furthermore, the text has been written to make it accessible to a broad readership while including all the important information necessary to understand the business model.

Aion Therapeutic izmaksā dividendes 0 CAD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Aion Therapeutic vai uzņēmums nedod dividendes.

Aion Therapeutic ISIN ir CA00905T1021.

Aion Therapeutic WKN ir A2QCBY.

Aion Therapeutic simbols ir AION.CN.

Pēdējo 12 mēnešu laikā Aion Therapeutic maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Aion Therapeutic plāno maksāt dividendes 0 CAD apmērā.

Aion Therapeutic pašreizējā dividendu rentabilitāte ir .

Aion Therapeutic maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Aion Therapeutic pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 CAD. Tas atbilst dividendes ražībai 0 %.

Aion Therapeutic tiek piešķirts nozarei "—".

Lai saņemtu pēdējo dividendu Aion Therapeutic apmērā 0 CAD, kas tika izmaksāta 11.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 11.07.2024..

Pēdējās dividendes izmaksa notika 11.07.2024..

Gadā 2023, Aion Therapeutic izmaksāja 0 CAD dividendes.

Aion Therapeutic dividendes tiek izmaksātas CAD.